RPAM
SRNE

Rhenman & Partners Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-72,535
Closed -$328K – 99
2014
Q3 		$328K Hold
72,535
– – 0.1% 98
2014
Q2 		$490K Buy
72,535
+23,400
+48% +$176K 0.15% 92
2014
Q1 		$630K Buy
+49,135
New +$544K 0.19% 87

Other funds holding SRNE

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.42% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Rhenman & Partners Asset Management's SRNE Position: Q4 2014 in Review

Rhenman & Partners Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2014, closing a stake of 72,535 shares — an estimated $328K sold.

Rhenman & Partners Asset Management first reported a position in SRNE in Q1 2014 and held it in 3 quarters. The position peaked at $630K in Q1 2014. 38 funds tracked by Wall St. Rank hold SRNE as of Q4 2014.

  • Rhenman & Partners Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 72,535 Sorrento Therapeutics, Inc. shares in Q4 2014, an estimated $328K.
  • Rhenman & Partners Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • Rhenman & Partners Asset Management's Sorrento Therapeutics, Inc. position peaked at $630K in Q1 2014.
  • 38 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.